These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21983442)

  • 1. Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.
    Gewald R; Rueger C; Grunwald C; Egerland U; Hoefgen N
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6652-6. PubMed ID: 21983442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
    Banerjee A; Patil S; Pawar MY; Gullapalli S; Gupta PK; Gandhi MN; Bhateja DK; Bajpai M; Sangana RR; Gudi GS; Khairatkar-Joshi N; Gharat LA
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6286-91. PubMed ID: 22944118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.
    Guo J; Watson A; Kempson J; Carlsen M; Barbosa J; Stebbins K; Lee D; Dodd J; Nadler SG; McKinnon M; Barrish J; Pitts WJ
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1935-8. PubMed ID: 19272774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.
    Endo Y; Kawai K; Asano T; Amano S; Asanuma Y; Sawada K; Ogura K; Nagata N; Ueo N; Takahashi N; Sonoda Y; Kamei N
    Bioorg Med Chem Lett; 2015 Feb; 25(3):649-53. PubMed ID: 25529739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
    Pitts WJ; Vaccaro W; Huynh T; Leftheris K; Roberge JY; Barbosa J; Guo J; Brown B; Watson A; Donaldson K; Starling GC; Kiener PA; Poss MA; Dodd JH; Barrish JC
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2955-8. PubMed ID: 15125967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities.
    Redondo M; Soteras I; Brea J; González-García A; Cadavid MI; Loza MI; Martinez A; Gil C; Campillo NE
    Eur J Med Chem; 2013; 70():781-8. PubMed ID: 24239625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold.
    Sánchez AI; Meneses R; Mínguez JM; Núñez A; Castillo RR; Filace F; Burgos C; Vaquero JJ; Álvarez-Builla J; Cortés-Cabrera A; Gago F; Terricabras E; Segarra V
    Org Biomol Chem; 2014 Jun; 12(24):4233-42. PubMed ID: 24838636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
    Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research.
    Jankowska A; Swierczek A; Chlon-Rzepa G; Pawlowski M; Wyska E
    Curr Med Chem; 2017; 24(7):673-700. PubMed ID: 28093982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation.
    Banerjee A; Yadav PS; Bajpai M; Sangana RR; Gullapalli S; Gudi GS; Gharat LA
    Bioorg Med Chem Lett; 2012 May; 22(9):3223-8. PubMed ID: 22487174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
    Torrisi C; Bisbocci M; Ingenito R; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
    Bioorg Med Chem Lett; 2010 Jan; 20(2):448-52. PubMed ID: 20015648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and SAR of novel Naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK).
    Cywin CL; Zhao BP; McNeil DW; Hrapchak M; Prokopowicz AS; Goldberg DR; Morwick TM; Gao A; Jakes S; Kashem M; Magolda RL; Soll RM; Player MR; Bobko MA; Rinker J; DesJarlais RL; Winters MP
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1415-8. PubMed ID: 12668002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
    Redondo M; Brea J; Perez DI; Soteras I; Val C; Perez C; Morales-García JA; Alonso-Gil S; Paul-Fernandez N; Martin-Alvarez R; Cadavid MI; Loza MI; Perez-Castillo A; Mengod G; Campillo NE; Martinez A; Gil C
    J Med Chem; 2012 Apr; 55(7):3274-84. PubMed ID: 22385507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.
    Endo Y; Kawai K; Asano T; Amano S; Asanuma Y; Sawada K; Onodera Y; Ueo N; Takahashi N; Sonoda Y; Kamei N; Irie T
    Bioorg Med Chem Lett; 2015 May; 25(9):1910-4. PubMed ID: 25866242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
    Gewald R; Grunwald C; Egerland U
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
    Redondo M; Zarruk JG; Ceballos P; Pérez DI; Pérez C; Perez-Castillo A; Moro MA; Brea J; Val C; Cadavid MI; Loza MI; Campillo NE; Martínez A; Gil C
    Eur J Med Chem; 2012 Jan; 47(1):175-85. PubMed ID: 22100138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biological screening, and molecular docking of quinazolinone and quinazolinethione as phosphodiesterase 7 inhibitors.
    Elfeky SM; Sobahi TR; Gineinah MM; Ahmed NS
    Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900211. PubMed ID: 31696968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.